Galectin Therapeutics Inc (GALT) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $3.14
• Market Cap: $207.62M
• EPS: $-0.60
• 52-Week High: $7.13
• 52-Week Low: $1.12

Market Sentiment

Galectin Therapeutics Inc currently has a Bearish sentiment score of -0.44.

About Galectin Therapeutics Inc

Galectin Therapeutics Inc. (GALT) is a clinical-stage biopharmaceutical company based in Norcross, Georgia, specializing in the discovery and development of innovative therapies targeting fibrotic diseases, cancer, and other severe medical conditions. The company's proprietary technology focuses on galectin proteins, which play critical roles in disease progression and tissue inflammation, positioning Galectin Therapeutics to address significant unmet medical needs. With a robust pipeline and...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Galectin Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does GALT pay dividends?

Galectin Therapeutics Inc (GALT) does not currently pay a regular dividend.

What is GALT's market cap?

Galectin Therapeutics Inc (GALT) has a market capitalization of $207.62M with a current stock price of $3.14.